Promoted Content
Promoted Content

Find Novel Neurology Drugs in Preclinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IkT-148x

            Therapeutic Area: Neurology Product Name: IkT-148x

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            Details:

            IkT-148x is c-Abl kinase inhibitor for treatment of Parkinson's disease and multiple system atrophy. A study revealed that c-Abl activates and regulates alpha-synuclein aggregation in the brains of MSA patients and in the brains of animal models of the disease.

            The University of Calgary

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): THX-160

            Therapeutic Area: Neurology Product Name: THX-160

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Therapix Biosciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 02, 2020

            Details:

            This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): QRA-244

            Therapeutic Area: Neurology Product Name: QRA-244

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 02, 2020

            Details:

            Poster titled "QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients " wail be presented MNDA 31st International Symposium on ALS/MND.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): HTL0022562

            Therapeutic Area: Neurology Product Name: HTL0022562

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals

            Deal Size: $10.0 million Upfront Cash: $380.0 million

            Deal Type: Collaboration December 01, 2020

            Details:

            Biohaven will get exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. The portfolio includes the lead candidate HTL0022562.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Bryostatin 1,Tretinoin

            Therapeutic Area: Neurology Product Name: APH-1104

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 01, 2020

            Details:

            The combination therapeutic consists of biodegradable polymer nanospheres co-encapsulating a Bryoid and a Retinoid to improve synergistically alpha-secretase (α-secretase) production and reduce -amyloid plaque generation.